Intermittent fasting improves hepatic end points in nonalcoholic fatty liver disease: A systematic review and meta-analysis

BACKGROUND AND AIMS: Despite NAFLD being the most prevalent liver disease globally, currently there are no FDA-approved treatments, and weight loss through caloric restriction and enhanced physical activity is the recommended treatment strategy. Intermittent fasting (IF) has been proposed as an alte...

Descripción completa

Detalles Bibliográficos
Autores principales: Lange, Marcia, Nadkarni, Devika, Martin, Lily, Newberry, Carolyn, Kumar, Sonal, Kushner, Tatyana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552959/
https://www.ncbi.nlm.nih.gov/pubmed/37534936
http://dx.doi.org/10.1097/HC9.0000000000000212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552959/
https://www.ncbi.nlm.nih.gov/pubmed/37534936
http://dx.doi.org/10.1097/HC9.0000000000000212

Ejemplares similares